keyword
MENU ▼
Read by QxMD icon Read
search

radioembolisation

keyword
https://www.readbyqxmd.com/read/27622200/treatment-response-after-radioembolisation-in-patients-with-hepatocellular-carcinoma-an-evaluation-with-dual-energy-computed-tomography
#1
Jens Altenbernd, Axel Wetter, Michael Forsting, Lale Umutlu
PURPOSE: The aim of this prospective study was to examine the diagnostic value of dual-energy CT (DECT) in the assessment of response of HCC after radioembolisation (RE). MATERIAL AND METHODS: 40 HCC patients with 82 measurable target lesions were included in this study. At baseline and follow-up examination target lesions were evaluated with (IU), AASLD and Choi measurement criteria. Disease control was defined as the sum of complete response (CR), partial response (PR), progression disease (PD) and stable disease (SD)...
2016: European Journal of Radiology Open
https://www.readbyqxmd.com/read/27307346/partition-model-based-99mtc-maa-spect-ct-predictive-dosimetry-compared-to-90y-tof-pet-ct-post-treatment-dosimetry-in-radioembolisation-of-hepatocellular-carcinoma-a-quantitative-agreement-comparison
#2
Silvano Gnesin, Laurent Canetti, Salim Adib, Nicolas Cherbuin, Marina Silva-Monteiro, Pierre Bize, Alban Denys, John O Prior, Sebastien Baechler, Ariane Boubaker
PURPOSE: (90)Y microsphere, selective internal radiation therapy (SIRT) is a valuable treatment in unresectable hepatocellular carcinoma (HCC). Partition-model predictive dosimetry relies on differential tumoral/non-tumoral perfusion evaluated on pre-treatment (99m)Tc macroaggregate albumin (MAA) single photon emission tomography (SPECT) / computed tomography (CT). The aim of this study was to evaluate the agreement between predictive dosimetry of (99m)Tc-MAA SPECT/CT and post-treatment dosimetry based on (90)Y time-of-flight (TOF) positron emission tomography (PET)/CT...
June 15, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27108297/liver-ct-for-vascular-mapping-during-radioembolisation-workup-comparison-of-an-early-and-late-arterial-phase-protocol
#3
Andor F van den Hoven, Manon N G J A Braat, Jip F Prince, Pieter J van Doormaal, Maarten S van Leeuwen, Marnix G E H Lam, Maurice A A J van den Bosch
OBJECTIVES: To compare right gastric (RGA) and segment 4 artery (A4) origin detection rates during radioembolisation workup between early and late arterial phase liver CT protocols. METHODS: 100 consecutive patients who underwent liver CT between May 2012-January 2015 with early or late arterial phase protocol (n = 50 each, 10- vs. 20-s post-threshold delay) were included. RGA/A4 origin detection rates, assessed by two raters, and contrast-to-noise ratio (CNR) of the hepatic artery relative to the portal vein were compared between the protocols...
January 2017: European Radiology
https://www.readbyqxmd.com/read/27020341/origin-dosimetric-effect-and-clinical-limitations-of-the-semi-empirical-body-surface-area-method-for-radioembolisation-using-yttrium-90-resin-microspheres
#4
Yung Hsiang Kao, Meir Lichtenstein
No abstract text is available yet for this article.
June 2016: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/26905230/yttrium-90-microsphere-radioembolisation-for-unresectable-hepatocellular-carcinoma
#5
REVIEW
Omar M Abdel-Rahman, Zeinab Elsayed
BACKGROUND: Hepatocellular carcinoma is the most common liver neoplasm and the fifth most common cancer worldwide. Moreover, its incidence has increased dramatically since the mid-2000s. While surgical resection and liver transplantation are the main curative treatments, only around 20% of people with early hepatocellular carcinoma may benefit from these therapies. Current treatment options for unresectable hepatocellular carcinoma include various ablative and trans-arterial therapies in addition to the drug sorafenib...
2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26638448/-about-juvenile-nasopharyngeal-angiofibroma
#6
V Urbain, P Meunier, B Otto
We report the case of a young man with a juvenile nasopharyngeal angiofibroma. In this paper, we will first remind the clinical signs of this pathology and its radiological appearance (localisation and extensions). Then we will explain how radioembolisation techniques were used to facilitate the surgical intervention. Finally we will discuss the histology of this tumor.
September 2015: Revue Médicale de Liège
https://www.readbyqxmd.com/read/26516379/sorafenib-for-the-treatment-of-hepatocellular-carcinoma-with-portal-vein-tumour-thrombosis-a-systematic-review-of-comparative-studies
#7
REVIEW
Xingshun Qi, Xiaozhong Guo
Sorafenib is the first-line treatment of choice for advanced hepatocellular carcinoma (HCC). However, the benefits of sorafenib in HCC patients with portal vein tumour thrombosis (PVTT) remain uncertain. Until now, a total of eight comparative studies have been identified for this systematic review. Four retrospective studies showed that hepatic arterial infusion chemotherapy, hepatic resection, and three-dimensional conformal radiotherapy might be superior to sorafenib in improving the overall survival. Two ongoing randomised controlled trials (RCTs) will compare the outcomes of transarterial chemoembolisation or radioembolisation with those of sorafenib for the treatment of HCC with PVTT...
2015: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/26327775/radioembolisation-and-portal-vein-embolization-before-resection-of-large-hepatocellular-carcinoma
#8
Fikri Bouazza, Arthur Poncelet, Camilo Alejandro Garcia, Philippe Delatte, Jean Luc Engelhom, Maria Gomez Galdon, Amélie Deleporte, Alain Hendlisz, Bruno Vanderlinden, Patrick Flamen, Vincent Donckier
Resectability of hepatocellular carcinoma in patients with chronic liver disease is dramatically limited by the need to preserve sufficient remnant liver in order to avoid postoperative liver insufficiency. Preoperative treatments aimed at downsizing the tumor and promoting hypertrophy of the future remnant liver may improve resectability and reduce operative morbidity. Here we report the case of a patient with a large hepatocellular carcinoma arising from chronic liver disease. Preoperative treatment, including tumor downsizing with transarterial radioembolization and induction of future remnant liver hypertrophy with right portal vein embolization, resulted in a 53% reduction in tumor volume and compensatory hypertrophy in the contralateral liver...
August 28, 2015: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/26238772/scientific-basis-of-personalised-tomographic-radiation-planning-for-radioembolisation-a-form-of-brachytherapy-planning
#9
Yung Hsiang Kao, Mark Goodwin, Sze Ting Lee, Meir Lichtenstein, Andrew Mark Scott
Today's tomographic imaging techniques such as catheter-directed CT and single photon emission computed tomography with integrated computed tomography may be used for pre-therapy radiation planning for radioembolisation based on prospective calculation of tissue radiation absorbed doses. We outline the scientific concepts that underlie modern personalised tomographic radiation planning for radioembolisation and highlight its similarities to brachytherapy planning.
October 2015: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/26116112/heterogeneity-of-microsphere-distribution-in-resected-liver-and-tumour-tissue-following-selective-intrahepatic-radiotherapy
#10
Jonas Högberg, Magnus Rizell, Ragnar Hultborn, Johanna Svensson, Olof Henrikson, Johan Mölne, Peter Gjertsson, Peter Bernhardt
BACKGROUND: Selective arterial radioembolisation of liver tumours has increased, because of encouraging efficacy reports; however, therapeutic parameters used in external beam therapy are not applicable for understanding and predicting potential toxicity and efficacy, necessitating further studies of the physical and biological characteristics of radioembolisation. The aim was to characterise heterogeneity in the distribution of microspheres on a therapeutically relevant geometric scale considering the range of yttrium-90 ((90)Y) β-particles...
December 2014: EJNMMI Research
https://www.readbyqxmd.com/read/25678128/selective-transarterial-radioembolisation-of-unresectable-liver-dominant-colorectal-cancer-refractory-to-chemotherapy
#11
Rita Golfieri, Cristina Mosconi, Emanuela Giampalma, Alberta Cappelli, Maria Cristina Galaverni, Cinzia Pettinato, Matteo Renzulli, Fabio Monari, Renzo Mazzarotto, Carmine Pinto, Bruna Angelelli
PURPOSE: The target lesion response (according to the Choi criteria), safety and survival following selective or superselective transarterial radioembolisation using yttrium-90-resin microspheres ((90)Y-RE) were evaluated in patients with unresectable, chemotherapy-refractory colorectal cancer liver metastases (mCRC). MATERIALS AND METHODS: A prospective case series evaluated 52 consecutive patients with mCRC who were treated at a single centre following a median of 2 lines of chemotherapy...
August 2015: La Radiologia Medica
https://www.readbyqxmd.com/read/25487708/selective-internal-radiation-therapy-sirt-with-yttrium-90-resin-microspheres-plus-standard-systemic-chemotherapy-regimen-of-folfox-versus-folfox-alone-as-first-line-treatment-of-non-resectable-liver-metastases-from-colorectal-cancer-the-sirflox-study
#12
RANDOMIZED CONTROLLED TRIAL
Peter Gibbs, Val Gebski, Mark Van Buskirk, Kenneth Thurston, David N Cade, Guy A Van Hazel
BACKGROUND: In colorectal cancer (CRC), unresectable liver metastases are linked to poor prognosis. Systemic chemotherapy with regimens such as FOLFOX (combination of infusional 5-fluorouracil, leucovorin and oxaliplatin) is the standard first-line treatment. The SIRFLOX trial was designed to assess the efficacy and safety of combining FOLFOX-based chemotherapy with Selective Internal Radiation Therapy (SIRT or radioembolisation) using yttrium-90 resin microspheres (SIR-SpheresR; Sirtex Medical Limited, North Sydney, Australia)...
December 1, 2014: BMC Cancer
https://www.readbyqxmd.com/read/25472660/radioembolisation-with-yttrium%C3%A2-90-microspheres-versus-sorafenib-for-treatment-of-advanced-hepatocellular-carcinoma-sarah-study-protocol-for-a-randomised-controlled-trial
#13
RANDOMIZED CONTROLLED TRIAL
Valérie Vilgrain, Mohamed Abdel-Rehim, Annie Sibert, Maxime Ronot, Rachida Lebtahi, Laurent Castéra, Gilles Chatellier
BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis. While sorafenib is the current recommended treatment for advanced HCC, radioembolisation (RE; also called selective internal radiation therapy or SIRT) with yttrium-90 microspheres has shown efficacy in cohort studies. However, there are no head-to-head trials comparing radiation therapy with yttrium-90 microspheres and sorafenib in advanced HCC. The SARAH trial has been designed to compare the efficacy and safety of sorafenib therapy and RE using yttrium-90 resin microspheres (SIR-Spheres™; Sirtex Medical Limited, North Sydney, Australia) in patients with advanced HCC...
December 3, 2014: Trials
https://www.readbyqxmd.com/read/25238135/mixed-ligand-complexes-of-yttrium-90-dialkyldithiocarbamates-with-1-10-phenanthroline-as-a-possible-agent-for-therapy-of-hepatocellular-carcinoma
#14
A Lopez, N Noiret, E Garin, N Lepareur
Yttrium-90 is a radioelement which has found wide use in targeted radionuclide therapy because of its attractive physical and chemical properties. Radioembolisation of hepatocellular carcinoma with radiolabelled Lipiodol is a method of choice. We have synthesised a series of alkyldithiocarbamate yttrium complexes, easily extracted into Lipiodol due to their high lipophilicity. Among the prepared series, a new radioconjugate, which is stable over an extended period of time, has been prepared, and could represent a potential treatment procedure for hepatocellular carcinoma...
December 2014: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/25097006/a-new-approach-for-dose-calculation-in-targeted-radionuclide-therapy-trt-based-on-collapsed-cone-superposition-validation-with-90-y
#15
Manuel Sanchez-Garcia, Isabelle Gardin, Rachida Lebtahi, Arnaud Dieudonné
To speed-up the absorbed dose (AD) computation while accounting for tissue heterogeneities, a Collapsed Cone (CC) superposition algorithm was developed and validated for (90)Y. The superposition was implemented with an Energy Deposition Kernel scaled with the radiological distance, along with CC acceleration. The validation relative to Monte Carlo simulations was performed on 6 phantoms involving soft tissue, lung and bone, a radioembolisation treatment and a simulated bone metastasis treatment. As a figure of merit, the relative AD difference (ΔAD) in low gradient regions (LGR), distance to agreement (DTA) in high gradient regions and the γ(1%,1 mm) criterion were used for the phantoms...
September 7, 2014: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/25011439/foxfire-protocol-an-open-label-randomised-phase-iii-trial-of-5-fluorouracil-oxaliplatin-and-folinic-acid-oxmdg-with-or-without-interventional-selective-internal-radiation-therapy-sirt-as-first-line-treatment-for-patients-with-unresectable-liver-only-or-liver
#16
RANDOMIZED CONTROLLED TRIAL
Susan J Dutton, Nicola Kenealy, Sharon B Love, Harpreet S Wasan, Ricky A Sharma
BACKGROUND: Colorectal cancer (CRC) is the second most common malignancy in Europe and a leading cause of cancer-related death. Almost 50% of patients with CRC develop liver metastases, which heralds a poor prognosis unless metastases can be downsized to surgical resection or ablation. The FOXFIRE trial examines the hypothesis that combining radiosensitising chemotherapy (OxMdG: oxaliplatin, 5-fluorouracil and folic acid) with Selective Internal Radiation Therapy (SIRT or radioembolisation) using yttrium-90 resin microspheres (SIR-Spheres®; Sirtex Medical Limited, North Sydney, Australia) as a first-line treatment for liver-dominant metastatic CRC will improve clinical outcomes when compared to OxMdG chemotherapy alone...
July 9, 2014: BMC Cancer
https://www.readbyqxmd.com/read/24964737/impaired-hepatic-gd-eob-dtpa-enhancement-after-radioembolisation-of-liver-malignancies
#17
Maciej Janusz Powerski, Christian Scheurig-Münkler, Bernd Hamm, Bernhard Gebauer
INTRODUCTION: To evaluate the uptake of the liver-specific magnetic resonance imaging (MRI) contrast agent gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) by functional liver parenchyma after radioembolisation (RE) of hepatic malignancies. METHODS: Uptake of Gd-EOB-DTPA prior to RE versus 60+/-24d and 126+/-32d after RE was compared in a group of 33 patients with primary or secondary hepatic malignancies. In patients who underwent single-lobe treatment, left and right lobes were compared 59+/-24 days after RE...
August 2014: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/24817083/perfusion-ct-best-predicts-outcome-after-radioembolization-of-liver-metastases-a-comparison-of-radionuclide-and-ct-imaging-techniques
#18
COMPARATIVE STUDY
Fabian Morsbach, Bert-Ram Sah, Lea Spring, Gilbert Puippe, Sonja Gordic, Burkhardt Seifert, Niklaus Schaefer, Thomas Pfammatter, Hatem Alkadhi, Caecilia S Reiner
OBJECTIVE: To determine the best predictor for the response to and survival with transarterial radioembolisation (RE) with (90)yttrium microspheres in patients with liver metastases. METHODS: Forty consecutive patients with liver metastases undergoing RE were evaluated with multiphase CT, perfusion CT and (99m)Tc-MAA SPECT. Arterial perfusion (AP) from perfusion CT, HU values from the arterial (aHU) and portal venous phase (pvHU) CT, and (99m)Tc-MAA uptake ratio of metastases were determined...
July 2014: European Radiology
https://www.readbyqxmd.com/read/24589204/transarterial-chemoembolisation-and-radioembolisation-for-the-treatment-of-primary-liver-cancer-and-secondary-liver-cancer-a-review-of-the-literature
#19
REVIEW
Lourens Bester, Baerbel Meteling, David Boshell, Terence C Chua, David L Morris
Liver-directed therapies are continuing to evolve in the field of interventional oncology and are gaining increasing use in the treatment of unresectable primary and secondary liver cancers. In this article, we review two liver-directed therapies that are currently used for the palliative treatment of primary and secondary hepatic tumours: transcatheter arterial chemoembolisation (TACE), including a new type of TACE with drug-eluting beads (DEB-TACE), and radioembolisation. The concept of these transcatheter intraarterial therapies is to selectively deliver high doses of anticancer treatment to the tumour...
2014: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/24531850/hepatocellular-carcinoma-clinical-frontiers-and-perspectives
#20
REVIEW
Jordi Bruix, Gregory J Gores, Vincenzo Mazzaferro
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death and is currently the main event leading to death in patients with cirrhosis. Evolving information suggests that the metabolic syndrome with non-alcoholic liver disease may be an important cause of HCC in addition to viral hepatitis and alcohol-induced liver disease. The molecular pathogenesis is extremely complex and heterogeneous. To date the molecular information has not impacted on treatment decisions. Periodic surveillance imaging of patients with cirrhosis is widely practiced, especially because diagnostic, radiographic criteria for early-stage HCC have been defined (including nodules between 1 and 2 cm) and effective treatment is available for tumours detected at an early stage...
May 2014: Gut
keyword
keyword
73282
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"